CXCR1 and diabetes mellitus: Recently, Citro et al. demonstrated that oral administration of ladarixin, which is a potent blocker of both CXCR1 and CXCR2, even reverted diabetes in recent onset diabetic NOD mice, thus identifying the Cxcr1/2 pathway as “master regulators” of diabetes pathogenesis [67].